This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects (NCT04573322), a randomized phase 1, phase 2 study. The primary outcome is Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04573322 |
| Phase | Phase 1, Phase 2 |
| Condition | SARS-CoV-2 (Covid19) |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Enrollment | 25 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Diffusion Pharmaceuticals Inc |
| Results posted | Yes |
2. Clinical Question
Population
People infected with SARS-CoV-2 (COVID-19) were the intended study population. The registry record does not report further eligibility criteria or a detailed description of the participants enrolled.
Intervention
The intervention was trans sodium crocetinate (TSC). In the lead-in phase, participants were assigned to listed dose groups, with TSC administered by IV bolus every 6 hours for up to 15 days. The randomized active group was to receive the optimum safe and tolerable dose determined in the lead-in phase.
Comparator
The randomized comparator was normal saline, in an equivalent volume by participant body weight, administered by IV bolus every 6 hours for up to 15 days. A saline comparator can help distinguish outcomes observed with the active treatment from outcomes occurring in the comparison group, but comparative results are not reported in the registry record.
Primary question
The primary endpoint concerns the incidence of treatment-emergent adverse events and is described as an overall summary of subjects with TEAEs in the lead-in phase. It measures the number of participants with an event during the stated follow-up period, rather than establishing that an event was caused by TSC. The registry record does not report an analyzed randomized comparison for this endpoint.
The study was designed to assess safety and efficacy, but the posted primary endpoint is safety and tolerability. The registry record lists additional outcomes concerning severity-scale changes, oxygenation, ventilator-free days, and hospital length of stay. It does not report results or analyses for those outcomes. Accordingly, the recorded lead-in counts can describe events within the dose groups, but they cannot answer whether TSC differed from saline on clinical outcomes.
3. Trial Design
NCT04573322 is recorded as a Phase 1 and Phase 2 study with randomized allocation and a parallel model. The registry enrollment is 25, and the study status is completed. The recorded start date is 2020-09-10 and the primary completion date is 2021-03-17. The study title describes an open-label pharmacokinetic and pharmacodynamic ascending-dose safety lead-in, followed by a single-center, placebo-controlled, double-blind adaptive pilot study.
The lead-in included TSC dose groups of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, and 1.5 mg/kg. Each description specifies IV bolus administration every 6 hours for up to 15 days. In the subsequent randomized portion, the active group was to receive the optimum safe and tolerable dose selected from the lead-in; the placebo group was to receive normal saline in an equivalent volume based on participant body weight, on the same stated schedule.
The registry records quadruple masking, while the study title distinguishes an open-label lead-in from a double-blind randomized portion. The record does not explain how the masking designation applies across these phases or which roles were masked. The protocol details beyond the listed arm descriptions, including how the adaptive feature operated, are not reported in the registry record.
The primary endpoint is the incidence of treatment-emergent adverse events, described for the lead-in phase and followed up to 70 days post-study drug administration. Secondary outcomes concern categorical improvement or worsening on the WHO Ordinal Severity Scale, ventilator-free days, hospital length of stay, time to return to baseline oxygenation, and pulse oximetry. The registry lists 7 outcome measures and 0 analyses. Thus, design features and planned questions are recorded, but analyzed treatment comparisons are not.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Phase 1 lead-in was conducted; however, the study was completed prior to initiation of Phase 2. Therefore, only data are reported for the lead-in phase, as no data were collected for Phase 2.
Overall Study
| Stage | Lead-in 0.25 mg/kg | Lead-in 0.50 mg/kg | Lead-in 1.0 mg/kg | Lead-in 1.5 mg/kg |
|---|---|---|---|---|
| STARTED | 6 | 6 | 7 | 6 |
| COMPLETED | 5 | 4 | 5 | 3 |
| NOT COMPLETED | 1 | 2 | 2 | 3 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: Phase 1 lead-in was conducted; however, the study was completed prior to initiation of Phase 2. Therefore, only data are reported for the lead-in phase, as no data were collected for Phase 2.
| Characteristic | Unit | Lead-in 0.25 mg/kg | Lead-in 0.50 mg/kg | Lead-in 1.0 mg/kg | Lead-in 1.5 mg/kg | Total |
|---|---|---|---|---|---|---|
| Participants analysed | 6 | 6 | 7 | 6 | 25 | |
| Age, Categorical: <=18 years | Participants | 0 | 0 | 0 | 0 | 0 |
| Age, Categorical: Between 18 and 65 years | Participants | 4 | 3 | 7 | 5 | 19 |
| Age, Categorical: >=65 years | Participants | 2 | 3 | 0 | 1 | 6 |
| Age, Continuous | years | 51.50 (SD 18.87) | 60.83 (SD 16.04) | 54.43 (SD 8.16) | 57.50 (SD 8.89) | 56.00 (SD 13.16) |
| Sex: Female, Male: Female | Participants | 3 | 2 | 4 | 4 | 13 |
| Sex: Female, Male: Male | Participants | 3 | 4 | 3 | 2 | 12 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): White | Participants | 6 | 6 | 7 | 6 | 25 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment: Romania | Participants | 6 | 6 | 7 | 6 | 25 |
6. Primary Endpoint
The registry lists the primary outcome as Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), measured over Up to 70 days post-study drug administration.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint is the incidence of treatment-emergent adverse events, under the safety and tolerability outcome. The stated measure is participants, and the outcome parameter is a count of participants. Its timeframe is up to 70 days post-study drug administration. The description specifies that the lead-in phase outcome is an overall summary of subjects with TEAEs.
A participant-count endpoint answers how many people experienced at least one event under the outcome definition. It is not the same as a count of all events: one person can have more than one event, but a participant-level count does not represent the total event burden. The registry record does not provide the operational definition used to classify TEAEs, the event-level data, or details about how repeat events were handled.
Safety endpoints are used to characterize adverse events observed during and after exposure, and to support assessment of tolerability. In general, an event described as treatment-emergent is one that arises or worsens after treatment begins; that timing alone does not establish that treatment caused it. Causal attribution requires additional clinical and analytic judgment, which is not reported in the registry record.
The posted primary endpoint description applies to the lead-in phase. Although the design also includes a randomized active group and a saline group, a randomized comparison of this endpoint is not reported in the registry record. The endpoint name and follow-up window therefore define the safety question, but the available record does not provide a complete analyzed estimate of that question.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record describes a completed study and lists an enrollment of 25, but completion status does not mean that results for every planned outcome are reported. The record lists 7 outcome measures and 0 analyses. It therefore does not provide inferential results for the primary endpoint or the listed secondary outcomes. No treatment-effect estimate, confidence interval, or hypothesis-test result for TSC versus saline is reported in the registry record.
The adverse-event information is limited to lead-in dose groups. For each group, the registry records participants at risk and participants affected by serious and other adverse events, as well as a death count. These counts are descriptive. They do not by themselves provide an adjusted comparison, a measure of uncertainty, or evidence that any event was caused by the study drug. The lead-in groups also do not constitute a reported randomized comparison with saline.
The serious-event record lists respiratory failure at 16.7% among the top serious terms. The denominator and the precise scope of that percentage are not reported in the registry record. It should not be interpreted as a rate across all enrolled participants or across all study phases without that information. Nor does a serious-event term establish causation.
For the primary endpoint, the registry specifies an observation window of up to 70 days post-study drug administration, but the counts reported by lead-in group do not explain how follow-up was completed for each participant. The record does not report the number assessed at each follow-up time, loss to follow-up, or handling of missing observations. Those omissions limit interpretation of the completeness of safety ascertainment.
General statistical interpretation depends on both an estimate and its uncertainty. A confidence interval, for example, describes a range of values compatible with the data and the analysis assumptions; it can indicate how precisely an effect has been estimated. No confidence interval is reported for the primary endpoint in the registry record, so precision cannot be assessed from an inferential estimate.
The study also lists efficacy-related outcomes, including severity-scale change and oxygenation measures. Their inclusion identifies questions the trial intended to examine, not findings. Since analyses and comparative results are not reported, the record does not establish the direction or magnitude of any efficacy outcome. The descriptive safety counts should therefore be read narrowly: they record events in the listed lead-in groups, while leaving comparative safety and efficacy conclusions unresolved.
Any sample-size illustrations associated with posted results are planning exercises rather than observed power. The registry record does not report the numerical planning outputs, the effect used for such an illustration, or a sample-size justification from the trial's own design. A planning calculation cannot substitute for the missing treatment-effect estimates, and it cannot show whether the study detected a clinically meaningful effect.
9. Statistical Methods Explained
The registry identifies a randomized, parallel study, with a lead-in phase followed by a randomized placebo-controlled portion. These are design features, not a full statistical analysis plan. The registry record does not report the planned statistical methods for the primary endpoint, the randomized comparison, or the secondary outcomes. The following concepts are general explanations of how such methods are commonly interpreted, not claims about analyses performed in this study.
What does a participant count represent?
A count of participants with an event treats each participant as the unit of summary. It answers whether a participant experienced an event under the specified definition, rather than how many separate events occurred. The distinction matters when one participant can experience repeated events: a participant-level count does not preserve the frequency or timing of those events. The primary endpoint is described as a count of participants with TEAEs, but event definitions and repeat-event handling are not reported in the registry record.
For a binary outcome, a common comparison might describe the number of participants with an event in each group and relate those counts to the group sizes. The record's adverse-event figures include participants at risk and participants affected, but it does not report a treatment-effect estimate or uncertainty interval for the primary endpoint. No new comparison should be inferred from the descriptive counts. In particular, the lead-in dose groups are not a substitute for the randomized TSC-versus-saline analysis.
Why does randomization matter?
In general, random allocation is intended to reduce systematic differences between treatment groups at the start of a study. A properly analyzed randomized comparison can support a causal interpretation more strongly than a comparison of nonrandomized dose cohorts, subject to issues such as missing outcomes, adherence, and analysis choices. Here, the registry records randomized allocation, but does not report the randomized group results or analysis populations. The intended design therefore cannot be used as evidence of a treatment difference on its own.
What can confidence intervals and tests add?
A confidence interval communicates uncertainty around an estimated effect under specified assumptions. A narrow interval generally indicates greater precision than a wide interval, while the interval's location indicates which effect values remain compatible with the data and method. A significance test addresses compatibility with a null hypothesis under a model; it does not measure clinical importance, prove causation, or establish that an effect is absent when a result is not statistically significant. No confidence intervals or test results for the outcomes are reported in the registry record.
The sample-size assumptions describe planning illustrations based on an observed effect: a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation. The effect to detect is expressed as a stated fraction of the observed effect. Such illustrations describe hypothetical future study requirements under assumptions; they are not observed power and do not establish that the completed study was adequately powered. The numerical planning illustrations and the effect used for them are not reported in the registry record. For non-time-to-event illustrations, the convention is participants per arm for 80% power; time-to-event illustrations use a total event count. These conventions do not supply missing trial results.
Why can event rates be difficult to compare?
Safety interpretation depends on how events are defined, how long participants are followed, and how completely outcomes are captured. A count of participants with an event may be affected by differences in exposure and observation time. General methods can account for time at risk or repeated events, but the registry record does not report an event-rate analysis, a time-to-event analysis, or a method for repeated events. The listed follow-up window alone does not establish that every participant had the same duration of observation.
Small or early-phase studies can produce imprecise estimates, particularly when events are uncommon. This is a general consideration, not a calculation about this trial. Without a reported estimate and its uncertainty, the degree of precision cannot be quantified. Similarly, dose-group counts may inform descriptive review of events but do not establish a dose-response relationship in the absence of a reported analysis.
What does an adaptive design imply?
In general, an adaptive study may allow specified design changes based on accumulating information, subject to safeguards and prespecified rules. The term appears in the study title, but the adaptation rules, decision criteria, and statistical adjustments are not reported in the registry record. It is therefore not possible to determine what adaptations were planned or implemented, or how they might affect interpretation of the final analyses.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists a primary safety endpoint and several secondary outcomes addressing severity, oxygenation, ventilator-free days, and length of stay. It records 7 outcome measures and 0 analyses. The list of outcomes shows that more than one question was planned, but the registry record does not report a multiplicity strategy, such as a hierarchy of tests or adjustment of significance levels. Without the planned analysis details, the relationship between any potential tests and the overall false-positive risk cannot be evaluated.
Missing-data handling is also not reported in the registry record. It does not state how missing follow-up, incomplete outcome assessments, or withdrawal from treatment would be handled in the analyses. For a safety endpoint with follow-up up to 70 days post-study drug administration, the completeness and duration of observation can affect how many events are captured. The record does not provide enough information to assess that issue.
The registry does not report the analysis populations for the primary or secondary outcomes. It is therefore unclear from the record which participants would be included in each analysis, or how participants with incomplete treatment or outcome data would be treated. The presence of randomized allocation does not resolve those questions; analysis-population definitions are part of the statistical methods.
No protocol-specific statistical plan, interim-analysis details, or sample-size justification is reported in the registry record. These omissions prevent assessment of whether outcome selection, adaptations, missingness, and multiplicity were addressed prospectively. They also mean that the listed outcome names should be understood as recorded study outcomes, not as evidence that prespecified analyses were completed or that particular results were obtained.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Lead-in 0.25 mg/kg | 1 | 6 | 16.7% |
| Lead-in 0.50 mg/kg | 1 | 6 | 16.7% |
| Lead-in 1.0 mg/kg | 0 | 7 | 0.0% |
| Lead-in 1.5 mg/kg | 0 | 6 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Lead-in 0.25 mg/kg | 1 of 6 |
| Lead-in 0.50 mg/kg | 0 of 6 |
| Lead-in 1.0 mg/kg | 0 of 7 |
| Lead-in 1.5 mg/kg | 0 of 6 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Lead-in 0.25 mg/kg | 3 of 6 |
| Lead-in 0.50 mg/kg | 4 of 6 |
| Lead-in 1.0 mg/kg | 5 of 7 |
| Lead-in 1.5 mg/kg | 2 of 6 |
Most frequent serious adverse event terms
| Event term | Organ system | Lead-in 0.25 mg/kg | Lead-in 0.50 mg/kg | Lead-in 1.0 mg/kg | Lead-in 1.5 mg/kg |
|---|---|---|---|---|---|
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | 1 of 6 | 1 of 6 | 0 of 7 | 0 of 6 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Lead-in 0.25 mg/kg | Lead-in 0.50 mg/kg | Lead-in 1.0 mg/kg | Lead-in 1.5 mg/kg |
|---|---|---|---|---|---|
| Interstitial Lung Disease | Respiratory, thoracic and mediastinal disorders | 3 of 6 | 0 of 6 | 0 of 7 | 0 of 6 |
| Hiatus Hernia | Gastrointestinal disorders | 1 of 6 | 1 of 6 | 0 of 7 | 0 of 6 |
| Contusion | Injury, poisoning and procedural complications | 0 of 6 | 2 of 6 | 0 of 7 | 0 of 6 |
| Hypoalbuminaemia | Metabolism and nutrition disorders | 0 of 6 | 1 of 6 | 0 of 7 | 1 of 6 |
| Coagulopathy | Blood and lymphatic system disorders | 0 of 6 | 0 of 6 | 1 of 7 | 0 of 6 |
| Bradycardia | Cardiac disorders | 0 of 6 | 0 of 6 | 1 of 7 | 0 of 6 |
| Congestive Cardiomyopathy | Cardiac disorders | 1 of 6 | 0 of 6 | 0 of 7 | 0 of 6 |
| Excessive Cerumen Production | Ear and labyrinth disorders | 0 of 6 | 0 of 6 | 1 of 7 | 0 of 6 |
| Diarrhoea | Gastrointestinal disorders | 0 of 6 | 1 of 6 | 0 of 7 | 0 of 6 |
| Dyspepsia | Gastrointestinal disorders | 1 of 6 | 0 of 6 | 0 of 7 | 0 of 6 |
Serious events with the highest arm-level rate: respiratory failure (16.7%).
The lead-in safety figures are counts of participants at risk and participants affected, separated into serious and other adverse-event categories for each listed dose group. In the 0.25 mg/kg group, the record lists 6 participants at risk for serious events and 1 affected; for other events it lists 6 at risk and 3 affected, with 1 death. In the 0.50 mg/kg group, the corresponding figures are 6 and 1 for serious events, 6 and 4 for other events, and 0 deaths. In the 1.0 mg/kg group, they are 7 and 0 for serious events, 7 and 5 for other events, and 0 deaths. In the 1.5 mg/kg group, they are 6 and 0 for serious events, 6 and 2 for other events, and 0 deaths.
These are descriptive records, not a randomized comparison. The registry does not report the methods used to classify events, the causal attribution of events, or a comparative estimate with uncertainty. The listed respiratory failure term at 16.7% is identified among the top serious terms; its denominator and scope are not reported in the registry record. The death count in the lowest listed dose group is recorded, but the record does not provide a cause or an attribution to study treatment. Counts alone cannot establish whether an event was caused by TSC or whether groups differed reliably.
12. What the Result Does, and Does Not, Mean
The registry record establishes that NCT04573322 was a completed Phase 1 and Phase 2 study of TSC in SARS-CoV-2-infected subjects, with a lead-in dose component and a planned randomized comparison with normal saline. It records a primary safety endpoint focused on treatment-emergent adverse events and gives descriptive event counts for the lead-in dose groups. Those details are useful for understanding the study's structure and the kinds of safety observations recorded.
The record does not report an analyzed estimate for the primary endpoint or comparative results for the randomized TSC and saline groups. It also does not report analyses for the listed severity, oxygenation, ventilation, or hospital-stay outcomes. The registry information therefore cannot establish the magnitude or precision of a treatment difference, nor can it establish a beneficial or harmful effect on clinical outcomes.
In general, observing an adverse event after treatment does not by itself show that treatment caused it. Likewise, seeing no recorded serious events in a dose group does not show that the risk is absent; interpretation depends on the number observed, duration and completeness of follow-up, and uncertainty around the estimate. Those inferential details are not reported for the outcomes in this record.
The lead-in counts and the randomized comparison answer different kinds of questions. Lead-in counts describe events recorded in dose groups during an ascending-dose phase. A randomized comparison, if analyzed and reported, would address differences between the active-treatment and saline groups under its analysis methods. The registry record includes the design for that comparison but does not include the comparative results.
Accordingly, the most defensible reading is descriptive rather than causal or comparative. The listed information characterizes the trial's plan and some lead-in safety counts, while leaving the primary endpoint analysis, efficacy findings, precision, and missing-data handling unresolved. No treatment recommendation follows from these registry entries.
13. Why This Trial Matters Statistically
This trial matters statistically because it combines an ascending-dose lead-in with a planned randomized comparison. These phases serve different roles: dose-group observations can contribute to evaluation of safety and tolerability, while randomization is intended to support a controlled comparison. Keeping those questions separate prevents descriptive lead-in counts from being mistaken for evidence of a treatment effect relative to saline.
The primary endpoint is a participant-level safety count over follow-up, and its interpretation depends on event definitions, exposure, and outcome ascertainment. The registry records counts across the lead-in dose groups but does not report a complete statistical analysis. The distinction between an event count and a treatment comparison is especially important when a study includes several doses and additional clinical outcomes.
The study title describes an adaptive design, and the registry records randomized allocation and quadruple masking. These design labels can have statistical implications, but the adaptation rules and the application of masking across study phases are not reported in the registry record. Without those details, readers cannot assess how design decisions were governed or how they were reflected in analysis.
Finally, a completed study with multiple recorded outcomes but no reported analyses illustrates why registry design information and results must be distinguished. Outcome names are not findings, and descriptive safety counts are not substitutes for effect estimates with uncertainty. The record is informative about the questions posed and the lead-in observations listed, while leaving the inferential answers unavailable.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The registry record provides limited information for interpreting the lead-in safety counts. It does not report the event-classification rules, how treatment-emergent events were distinguished from pre-existing conditions, how relatedness to TSC was assessed, or how repeat events were handled. The meaning of the serious and other adverse-event categories therefore cannot be fully evaluated from the record alone.
The listed figures do not include an uncertainty estimate or a reported statistical comparison. The record also does not state how much follow-up each participant completed, whether follow-up differed by group, or how missing safety observations were handled. Although the endpoint timeframe is up to 70 days post-study drug administration, that wording does not establish complete observation through the full period for all participants.
The reported serious-event term respiratory failure is accompanied by 16.7%, but its denominator and precise scope are not reported in the registry record. The death count is listed for the 0.25 mg/kg lead-in group, but cause and treatment attribution are not reported. These details limit interpretation of both the named event and the death information.
The record describes a randomized placebo-controlled phase, but does not report its outcome results or analysis populations. It also does not explain the adaptive rules, the relation between the masking designation and the open-label lead-in, or the statistical plan. Consequently, the lead-in counts cannot be used to infer the outcome of the randomized comparison, and the record does not support a complete assessment of efficacy, comparative safety, or precision.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects — NCT04573322.
- Registry record last updated 2022-04-14; status last verified 2022-04.
- Results first posted 2022-04-01.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT04573322 is recorded as a completed Phase 1 and Phase 2 study with randomized allocation and a parallel model. It enrolled 25 participants and investigated trans sodium crocetinate in people infected with SARS-CoV-2 (COVID-19). The study title describes an open-label ascending-dose lead-in followed by a single-center, placebo-controlled, double-blind adaptive pilot study. The registry records quadruple masking.
The primary endpoint concerns the incidence of treatment-emergent adverse events, with a lead-in phase summary and a timeframe of up to 70 days post-study drug administration. The record lists serious and other adverse-event counts by lead-in dose group, as well as a death count for each group. It also lists secondary outcomes related to severity, oxygenation, ventilator-free days, and hospital length of stay.
The registry records 7 outcome measures and 0 analyses. Comparative outcome estimates, uncertainty intervals, analysis populations, missing-data methods, and details of the adaptive rules are not reported in the registry record. The lead-in counts are descriptive and do not supply the missing randomized treatment comparison.